{"pmid":32472408,"title":"COVID-19 Pandemic and Surgical Oncology: Preserving the Academic Mission.","text":["COVID-19 Pandemic and Surgical Oncology: Preserving the Academic Mission.","BACKGROUND: The global pandemic of respiratory disease cause by the novel human coronavirus (SARS-CoV-2) has caused untold suffering, loss of life and upheaval in society. The pandemic has lead to massive redirection of health care resources to treat the surge of COVID-19 patients, and enforcement of social distancing to reduce the rate of transmission. METHODS: Editorial Board members provided observations of the implications of the pandemic on academic surgical oncology. RESULTS: Delivery of health care to other populations including cancer patients has been significantly disrupted. The implications both short term and long term threaten preservation of the academic mission in medicine at large, and certainly in the field of surgical oncology. CONCLUSIONS: The effects on surgical oncology training, research and clinical trials are major.","Ann Surg Oncol","Pawlik, Timothy M","Tyler, Douglas S","Sumer, Baran","Meric-Bernstam, Funda","Okereke, Ikenna C","Beane, Joal D","Dedhia, Priya H","Ejaz, Aslam","McMasters, Kelly M","Tanabe, Kenneth K","32472408"],"abstract":["BACKGROUND: The global pandemic of respiratory disease cause by the novel human coronavirus (SARS-CoV-2) has caused untold suffering, loss of life and upheaval in society. The pandemic has lead to massive redirection of health care resources to treat the surge of COVID-19 patients, and enforcement of social distancing to reduce the rate of transmission. METHODS: Editorial Board members provided observations of the implications of the pandemic on academic surgical oncology. RESULTS: Delivery of health care to other populations including cancer patients has been significantly disrupted. The implications both short term and long term threaten preservation of the academic mission in medicine at large, and certainly in the field of surgical oncology. CONCLUSIONS: The effects on surgical oncology training, research and clinical trials are major."],"journal":"Ann Surg Oncol","authors":["Pawlik, Timothy M","Tyler, Douglas S","Sumer, Baran","Meric-Bernstam, Funda","Okereke, Ikenna C","Beane, Joal D","Dedhia, Priya H","Ejaz, Aslam","McMasters, Kelly M","Tanabe, Kenneth K"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32472408","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1245/s10434-020-08563-x","topics":["Prevention"],"weight":1,"_version_":1668255193308856322,"score":9.490897,"similar":[{"pmid":32423292,"title":"Management of the Clinical and Academic Mission in an Urban Otolaryngology Department During the COVID-19 Global Crisis.","text":["Management of the Clinical and Academic Mission in an Urban Otolaryngology Department During the COVID-19 Global Crisis.","OBJECTIVE: The objective of this study was to assess the strategic changes implemented in the departmental mission to continue safe delivery of otolaryngology care and to support the broader institutional mission during the COVID-19 pandemic response. STUDY DESIGN: Retrospective assessment was performed to the response and management strategy developed to transform the clinical and academic enterprise. SETTING: Large urban tertiary care referral center. RESULTS: The departmental structure was reorganized along new clinical teams to effectively meet the system directives for provision of otolaryngology care and support for inpatient cases of COVID-19. A surge deployment schedule was developed to assist frontline colleagues with clinical support as needed. Outpatient otolaryngology was consolidated across the system with conversion of the majority of visits to telehealth. Operative procedures were prioritized to ensure throughput for emergent and time-critical urgent procedures. A tracheostomy protocol was developed to guide management of emergent and elective airways. Educational and research efforts were redirected to focus on otolaryngology care in the clinical context of the COVID-19 crisis. CONCLUSION: Emergence of the COVID-19 global health crisis has challenged delivery of otolaryngology care in an unparalleled manner. The concerns for preserving health of the workforce while ethically addressing patient career needs in a timely manner has created significant dilemmas. A proactive, thoughtful approach that reorganizes the overall departmental effort through provider and staff engagement can facilitate the ability to meet the needs of otolaryngology patients and to support the greater institutional mission to combat the pandemic.","Otolaryngol Head Neck Surg","Batra, Pete S","LoSavio, Phillip S","Michaelides, Elias","Revenaugh, Peter C","Tajudeen, Bobby A","Al-Khudari, Samer","Husain, Inna","Papagiannopoulos, Peter","Smith, Ryan","Stenson, Kerstin M","Wiet, R Mark","32423292"],"abstract":["OBJECTIVE: The objective of this study was to assess the strategic changes implemented in the departmental mission to continue safe delivery of otolaryngology care and to support the broader institutional mission during the COVID-19 pandemic response. STUDY DESIGN: Retrospective assessment was performed to the response and management strategy developed to transform the clinical and academic enterprise. SETTING: Large urban tertiary care referral center. RESULTS: The departmental structure was reorganized along new clinical teams to effectively meet the system directives for provision of otolaryngology care and support for inpatient cases of COVID-19. A surge deployment schedule was developed to assist frontline colleagues with clinical support as needed. Outpatient otolaryngology was consolidated across the system with conversion of the majority of visits to telehealth. Operative procedures were prioritized to ensure throughput for emergent and time-critical urgent procedures. A tracheostomy protocol was developed to guide management of emergent and elective airways. Educational and research efforts were redirected to focus on otolaryngology care in the clinical context of the COVID-19 crisis. CONCLUSION: Emergence of the COVID-19 global health crisis has challenged delivery of otolaryngology care in an unparalleled manner. The concerns for preserving health of the workforce while ethically addressing patient career needs in a timely manner has created significant dilemmas. A proactive, thoughtful approach that reorganizes the overall departmental effort through provider and staff engagement can facilitate the ability to meet the needs of otolaryngology patients and to support the greater institutional mission to combat the pandemic."],"journal":"Otolaryngol Head Neck Surg","authors":["Batra, Pete S","LoSavio, Phillip S","Michaelides, Elias","Revenaugh, Peter C","Tajudeen, Bobby A","Al-Khudari, Samer","Husain, Inna","Papagiannopoulos, Peter","Smith, Ryan","Stenson, Kerstin M","Wiet, R Mark"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32423292","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1177/0194599820929613","keywords":["covid-19","novel coronavirus","otolaryngology","pandemic","telehealth","tracheostomy"],"topics":["Prevention"],"weight":1,"_version_":1667252837798641664,"score":229.84145},{"pmid":32348043,"title":"[Oncology: navigating the COVID-19 Pandemic and Steer the Course].","text":["[Oncology: navigating the COVID-19 Pandemic and Steer the Course].","Medical oncologists are steering a difficult course during the COVID-19 pandemic between three opposing forces : revisiting optimal standards of cancer care, facing constantly evolving shortages as some resources are being redirected, and acknowledging the paradoxical need to keep patients away from the health care facility. This article compiles recommendations fr om cancer societies and expert opinions to provide guidance and practical solutions for the oncology clinic. We propose that optimal standards of care be upheld, and short-term safety concerns due to exposure to SARS-CoV-2 be weighed against a long-term compromise in cancer prognosis when deciding on adjustments in cancer care. Proper mitigation strategies in the clinic and use of less resource-heavy but equivalent treatment alternatives often allow optimal cancer care. The magnitude of benefit of cancer treatments needs to be systematically considered.","Rev Med Suisse","Zimmermann, Stefan","Dietrich, Pierre-Yves","Michielin, Olivier","Betticher, Daniel","Peters, Solange","32348043"],"abstract":["Medical oncologists are steering a difficult course during the COVID-19 pandemic between three opposing forces : revisiting optimal standards of cancer care, facing constantly evolving shortages as some resources are being redirected, and acknowledging the paradoxical need to keep patients away from the health care facility. This article compiles recommendations fr om cancer societies and expert opinions to provide guidance and practical solutions for the oncology clinic. We propose that optimal standards of care be upheld, and short-term safety concerns due to exposure to SARS-CoV-2 be weighed against a long-term compromise in cancer prognosis when deciding on adjustments in cancer care. Proper mitigation strategies in the clinic and use of less resource-heavy but equivalent treatment alternatives often allow optimal cancer care. The magnitude of benefit of cancer treatments needs to be systematically considered."],"journal":"Rev Med Suisse","authors":["Zimmermann, Stefan","Dietrich, Pierre-Yves","Michielin, Olivier","Betticher, Daniel","Peters, Solange"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32348043","source":"PubMed","week":"202018|Apr 27 - May 03","topics":["Prevention"],"weight":1,"_version_":1666138495383502849,"score":193.4337},{"pmid":32369430,"title":"Upholding the Tripartite Mission in Times of Crisis: Purpose and Perseverance in the COVID-19 Pandemic.","text":["Upholding the Tripartite Mission in Times of Crisis: Purpose and Perseverance in the COVID-19 Pandemic.","Academic otolaryngology has historically comprised a tripartite mission of research, education, and clinical care. This mission is greatly strained by the COVID-19 pandemic. Research laboratories are fallow, surgical cases are deferred, and clerkships are canceled. Otolaryngologists are adapting to new circumstances ranging from virtual patient care to urgent procedures in protective gear to deployment to provisional field hospitals. Amid these operational challenges, the specialty is demonstrating extraordinary resilience and grit, discovering new ways to serve learners, colleagues, and communities. Statements from leaders in otolaryngology reveal selfless acts and purposefulness. Necessity has spurred innovation in education, science, and novel models of care. Paragons strike notes of hope, inspiring us to persevere and serve. This commentary explores the present challenges and offers a vision for upholding the academic mission.","Otolaryngol Head Neck Surg","Standiford, Taylor","Shuman, Andrew G","Fessell, David","Brenner, Michael J","Bradford, Carol R","32369430"],"abstract":["Academic otolaryngology has historically comprised a tripartite mission of research, education, and clinical care. This mission is greatly strained by the COVID-19 pandemic. Research laboratories are fallow, surgical cases are deferred, and clerkships are canceled. Otolaryngologists are adapting to new circumstances ranging from virtual patient care to urgent procedures in protective gear to deployment to provisional field hospitals. Amid these operational challenges, the specialty is demonstrating extraordinary resilience and grit, discovering new ways to serve learners, colleagues, and communities. Statements from leaders in otolaryngology reveal selfless acts and purposefulness. Necessity has spurred innovation in education, science, and novel models of care. Paragons strike notes of hope, inspiring us to persevere and serve. This commentary explores the present challenges and offers a vision for upholding the academic mission."],"journal":"Otolaryngol Head Neck Surg","authors":["Standiford, Taylor","Shuman, Andrew G","Fessell, David","Brenner, Michael J","Bradford, Carol R"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32369430","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1177/0194599820922986","keywords":["covid-19","education","health care workers","pandemic","patient care","research","safety"],"topics":["General Info"],"weight":1,"_version_":1666138496294715392,"score":183.35641},{"pmid":32401360,"title":"Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance.","text":["Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance.","INTRODUCTION: A pandemic coronavirus, SARS-CoV-2, causes COVID-19, a potentially life-threatening respiratory disease. Patients with cancer may have compromised immunity due to their malignancy and/or treatment, and may be at elevated risk of severe COVID-19. Community transmission of COVID-19 could overwhelm health care services, compromising delivery of cancer care. This interim consensus guidance provides advice for clinicians managing patients with cancer during the pandemic. MAIN RECOMMENDATIONS: During the COVID-19 pandemic: In patients with cancer with fever and/or respiratory symptoms, consider causes in addition to COVID-19, including other infections and therapy-related pneumonitis. For suspected or confirmed COVID-19, discuss temporary cessation of cancer therapy with a relevant specialist. Provide information on COVID-19 for patients and carers. Adopt measures within cancer centres to reduce risk of nosocomial SARS-CoV-2 acquisition; support population-wide social distancing; reduce demand on acute services; ensure adequate staffing; and provide culturally safe care. Measures should be equitable, transparent and proportionate to the COVID-19 threat. Consider the risks and benefits of modifying cancer therapies due to COVID-19. Communicate treatment modifications, and review once health service capacity allows. Consider potential impacts of COVID-19 on the blood supply and availability of stem cell donors. Discuss and document goals of care, and involve palliative care services in contingency planning. CHANGES IN MANAGEMENT AS A RESULT OF THIS STATEMENT: This interim consensus guidance provides a framework for clinicians managing patients with cancer during the COVID-19 pandemic. In view of the rapidly changing situation, clinicians must also monitor national, state, local and institutional policies, which will take precedence. ENDORSED BY: Australasian Leukaemia and Lymphoma Group; Australasian Lung Cancer Trials Group; Australian and New Zealand Children's Haematology/Oncology Group; Australia and New Zealand Society of Palliative Medicine; Australasian Society for Infectious Diseases; Bone Marrow Transplantation Society of Australia and New Zealand; Cancer Council Australia; Cancer Nurses Society of Australia; Cancer Society of New Zealand; Clinical Oncology Society of Australia; Haematology Society of Australia and New Zealand; National Centre for Infections in Cancer; New Zealand Cancer Control Agency; New Zealand Society for Oncology; and Palliative Care Australia.","Med J Aust","Weinkove, Robert","McQuilten, Zoe K","Adler, Jonathan","Agar, Meera R","Blyth, Emily","Cheng, Allen C","Conyers, Rachel","Haeusler, Gabrielle M","Hardie, Claire","Jackson, Christopher","Lane, Steven W","Middlemiss, Tom","Mollee, Peter","Mulligan, Stephen P","Ritchie, David","Ruka, Myra","Solomon, Benjamin","Szer, Jeffrey","Thursky, Karin A","Wood, Erica M","Worth, Leon J","Yong, Michelle K","Slavin, Monica A","Teh, Benjamin W","32401360"],"abstract":["INTRODUCTION: A pandemic coronavirus, SARS-CoV-2, causes COVID-19, a potentially life-threatening respiratory disease. Patients with cancer may have compromised immunity due to their malignancy and/or treatment, and may be at elevated risk of severe COVID-19. Community transmission of COVID-19 could overwhelm health care services, compromising delivery of cancer care. This interim consensus guidance provides advice for clinicians managing patients with cancer during the pandemic. MAIN RECOMMENDATIONS: During the COVID-19 pandemic: In patients with cancer with fever and/or respiratory symptoms, consider causes in addition to COVID-19, including other infections and therapy-related pneumonitis. For suspected or confirmed COVID-19, discuss temporary cessation of cancer therapy with a relevant specialist. Provide information on COVID-19 for patients and carers. Adopt measures within cancer centres to reduce risk of nosocomial SARS-CoV-2 acquisition; support population-wide social distancing; reduce demand on acute services; ensure adequate staffing; and provide culturally safe care. Measures should be equitable, transparent and proportionate to the COVID-19 threat. Consider the risks and benefits of modifying cancer therapies due to COVID-19. Communicate treatment modifications, and review once health service capacity allows. Consider potential impacts of COVID-19 on the blood supply and availability of stem cell donors. Discuss and document goals of care, and involve palliative care services in contingency planning. CHANGES IN MANAGEMENT AS A RESULT OF THIS STATEMENT: This interim consensus guidance provides a framework for clinicians managing patients with cancer during the COVID-19 pandemic. In view of the rapidly changing situation, clinicians must also monitor national, state, local and institutional policies, which will take precedence. ENDORSED BY: Australasian Leukaemia and Lymphoma Group; Australasian Lung Cancer Trials Group; Australian and New Zealand Children's Haematology/Oncology Group; Australia and New Zealand Society of Palliative Medicine; Australasian Society for Infectious Diseases; Bone Marrow Transplantation Society of Australia and New Zealand; Cancer Council Australia; Cancer Nurses Society of Australia; Cancer Society of New Zealand; Clinical Oncology Society of Australia; Haematology Society of Australia and New Zealand; National Centre for Infections in Cancer; New Zealand Cancer Control Agency; New Zealand Society for Oncology; and Palliative Care Australia."],"journal":"Med J Aust","authors":["Weinkove, Robert","McQuilten, Zoe K","Adler, Jonathan","Agar, Meera R","Blyth, Emily","Cheng, Allen C","Conyers, Rachel","Haeusler, Gabrielle M","Hardie, Claire","Jackson, Christopher","Lane, Steven W","Middlemiss, Tom","Mollee, Peter","Mulligan, Stephen P","Ritchie, David","Ruka, Myra","Solomon, Benjamin","Szer, Jeffrey","Thursky, Karin A","Wood, Erica M","Worth, Leon J","Yong, Michelle K","Slavin, Monica A","Teh, Benjamin W"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32401360","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.5694/mja2.50607","keywords":["covid-19","hematologic neoplasms","immunosuppression","virus diseases"],"locations":["Australian","Australia","New Zealand","Australasian","Australia","New Zealand","Australia","New Zealand","Cancer"],"countries":["Australia","New Zealand"],"countries_codes":["AUS|Australia","NZL|New Zealand"],"topics":["Prevention"],"weight":1,"_version_":1666714494778212353,"score":182.5071},{"pmid":32330858,"pmcid":"PMC7136871","title":"Head and neck oncology during the COVID-19 pandemic: Reconsidering traditional treatment paradigms in light of new surgical and other multilevel risks.","text":["Head and neck oncology during the COVID-19 pandemic: Reconsidering traditional treatment paradigms in light of new surgical and other multilevel risks.","The COVID-19 pandemic demands reassessment of head and neck oncology treatment paradigms. Head and neck cancer (HNC) patients are generally at high-risk for COVID-19 infection and severe adverse outcomes. Further, there are new, multilevel COVID-19-specific risks to patients, surgeons, health care workers (HCWs), institutions and society. Urgent guidance in the delivery of safe, quality head and neck oncologic care is needed. Novel barriers to safe HNC surgery include: (1) imperfect presurgical screening for COVID-19; (2) prolonged SARS-CoV-2 aerosolization; (3) occurrence of multiple, potentially lengthy, aerosol generating procedures (AGPs) within a single surgery; (4) potential incompatibility of enhanced personal protective equipment (PPE) with routine operative equipment; (5) existential or anticipated PPE shortages. Additionally, novel, COVID-19-specific multilevel risks to HNC patients, HCWs and institutions, and society include: use of immunosuppressive therapy, nosocomial COVID-19 transmission, institutional COVID-19 outbreaks, and, at some locations, societal resource deficiencies requiring health care rationing. Traditional head and neck oncology doctrines require reassessment given the extraordinary COVID-19-specific risks of surgery. Emergent, comprehensive management of these novel, multilevel surgical risks are needed. Until these risks are managed, we temporarily favor nonsurgical therapy over surgery for most mucosal squamous cell carcinomas, wherein surgery and nonsurgical therapy are both first-line options. Where surgery is traditionally preferred, we recommend multidisciplinary evaluation of multilevel surgical-risks, discussion of possible alternative nonsurgical therapies and shared-decision-making with the patient. Where surgery remains indicated, we recommend judicious preoperative planning and development of COVID-19-specific perioperative protocols to maximize the safety and quality of surgical and oncologic care.","Oral Oncol","Day, Andrew T","Sher, David J","Lee, Rebecca C","Truelson, John M","Myers, Larry L","Sumer, Baran D","Stankova, Lenka","Tillman, Brittny N","Hughes, Randall S","Khan, Saad A","Gordin, Eli A","32330858"],"abstract":["The COVID-19 pandemic demands reassessment of head and neck oncology treatment paradigms. Head and neck cancer (HNC) patients are generally at high-risk for COVID-19 infection and severe adverse outcomes. Further, there are new, multilevel COVID-19-specific risks to patients, surgeons, health care workers (HCWs), institutions and society. Urgent guidance in the delivery of safe, quality head and neck oncologic care is needed. Novel barriers to safe HNC surgery include: (1) imperfect presurgical screening for COVID-19; (2) prolonged SARS-CoV-2 aerosolization; (3) occurrence of multiple, potentially lengthy, aerosol generating procedures (AGPs) within a single surgery; (4) potential incompatibility of enhanced personal protective equipment (PPE) with routine operative equipment; (5) existential or anticipated PPE shortages. Additionally, novel, COVID-19-specific multilevel risks to HNC patients, HCWs and institutions, and society include: use of immunosuppressive therapy, nosocomial COVID-19 transmission, institutional COVID-19 outbreaks, and, at some locations, societal resource deficiencies requiring health care rationing. Traditional head and neck oncology doctrines require reassessment given the extraordinary COVID-19-specific risks of surgery. Emergent, comprehensive management of these novel, multilevel surgical risks are needed. Until these risks are managed, we temporarily favor nonsurgical therapy over surgery for most mucosal squamous cell carcinomas, wherein surgery and nonsurgical therapy are both first-line options. Where surgery is traditionally preferred, we recommend multidisciplinary evaluation of multilevel surgical-risks, discussion of possible alternative nonsurgical therapies and shared-decision-making with the patient. Where surgery remains indicated, we recommend judicious preoperative planning and development of COVID-19-specific perioperative protocols to maximize the safety and quality of surgical and oncologic care."],"journal":"Oral Oncol","authors":["Day, Andrew T","Sher, David J","Lee, Rebecca C","Truelson, John M","Myers, Larry L","Sumer, Baran D","Stankova, Lenka","Tillman, Brittny N","Hughes, Randall S","Khan, Saad A","Gordin, Eli A"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330858","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.oraloncology.2020.104684","keywords":["covid-19 pandemic","head and neck cancer","head and neck oncology","mucosal squamous cell carcinoma","multilevel risk","risk stratification","sars-cov-2","surgical barriers","surgical risk","treatment paradigms"],"topics":["Prevention"],"weight":1,"_version_":1666138494701928448,"score":180.32013}]}